Research prototype, not medical advice.

08 — Cellular senescence

"Antagonistic" hallmark (López-Otín et al., Cell 2023, doi:10.1016/j.cell.2022.11.001). In plain terms: a damaged cell can "retire" instead of dividing, which protects it from cancer. But these "zombie" cells accumulate with age and poison their neighbours with inflammatory signals.

1. Definition

Senescence is a lasting halt of cell division, triggered by stress: telomeres that are too short, DNA damage, an activated oncogene, mitochondrial stress. The first to observe it was Hayflick, in human cells in culture that stopped dividing after a finite number of divisions (Hayflick 1965, doi:10.1016/0014-4827(65)90211-9). Senescent cells do not die: they resist apoptosis and secrete an inflammatory cocktail, the SASP (senescence-associated secretory phenotype). Useful in the short term (wound healing, tumour suppression), senescence becomes harmful when the cells accumulate and are no longer cleared (Gorgoulis 2019, doi:10.1016/j.cell.2019.10.005).

2. Mechanisms and sources

Two main "brakes". The p53 → p21 pathway reacts quickly to DNA damage; the p16^INK4a → Rb pathway maintains the arrest over time. p16^INK4a serves as a marker: in blood T lymphocytes, its level rises exponentially with age and with smoking and a sedentary lifestyle (Liu 2009, doi:10.1111/j.1474-9726.2009.00489.x).

Triggers. Telomere shortening, DNA damage (radiation, chemotherapy), oncogene activation, ROS and mitochondrial dysfunction, protein stress. Review: Muñoz-Espín & Serrano 2014, doi:10.1038/nrm3823.

The SASP, a double-edged sword. It is a mixture of cytokines (IL-6, IL-8, IL-1α), chemokines, growth factors and enzymes that degrade the matrix (Coppé 2008, doi:10.1371/journal.pbio.0060301). It is driven by NF-κB, the inflammasome and IL-1 (Acosta 2013, doi:10.1038/ncb2784), and partly by mTOR (Laberge 2015, doi:10.1038/ncb3195). The SASP can make neighbouring cells senescent: this is called "paracrine" senescence.

Beneficial roles. Senescence blocks precancerous cells, helps wound healing (transient senescence via PDGF-AA, Demaria 2014, doi:10.1016/j.devcel.2014.11.012) and takes part in embryonic development. The problem comes from chronic accumulation, when the immune system no longer clears these cells.

Causal evidence in mice. Genetically eliminating p16-positive cells (INK-ATTAC model):

3. Symptoms and clinical manifestations

Senescent cells accumulate in the tissues associated with the following diseases (Childs 2017, doi:10.1038/nrd.2017.116; Gasek 2021, doi:10.1038/s43587-021-00121-8):

4. Interactions with the other hallmarks

5. Existing or investigational remedies

Two families: senolytics selectively kill senescent cells (intermittent dosing, "hit and run"); senomorphics block their SASP without killing them.

InterventionTargetLevel of evidenceKey resultSource
Dasatinib + quercetin (D+Q)Anti-apoptotic pathways (SCAPs)PreclinicalDiscovered by transcriptome analysis; in old mice, improves physical function and extends remaining survival by about 36 %Zhu 2015, doi:10.1111/acel.12344; Xu 2018, doi:10.1038/s41591-018-0092-9
D+Q in pulmonary fibrosis—Open-label human phase 1 trial (n=14)Feasible; walking distance and speed improved; no change in lung functionJustice 2019, doi:10.1016/j.ebiom.2018.12.052
D+Q in diabetic kidney disease—Human phase 1 trial (n=9)Fewer senescent cells in fat and skin 11 days after 3 days of treatment: first direct evidence in humansHickson 2019, doi:10.1016/j.ebiom.2019.08.069
D+Q in postmenopausal osteoporosis—Human phase 2 trial (RCT, n=60)No overall effect on bone; modest benefit in women with a high senescent burdenFarr 2024, doi:10.1038/s41591-024-03096-2
D+Q in mild Alzheimer's—Human phase 1 trial (n=5)Dasatinib reaches the cerebrospinal fluid, quercetin does not; acceptable tolerabilityGonzales 2023, doi:10.1038/s41591-023-02543-w
Fisetin (flavonoid)SenolyticPreclinical; human phase 1-2 trials: knee osteoarthritis completed (n=75, NCT04210986, results posted on ClinicalTrials.gov, not yet published); AFFIRM frailty trials ongoing (NCT03430037, NCT03675724, planned end Nov. 2026)The most potent of the flavonoids tested; extends mouse life even when started late. No efficacy shown in humans to dateYousefzadeh 2018, doi:10.1016/j.ebiom.2018.09.015; https://clinicaltrials.gov/study/NCT04210986; https://clinicaltrials.gov/study/NCT03430037; https://clinicaltrials.gov/study/NCT03675724
Navitoclax (ABT-263)BCL-2/BCL-xLPreclinical (in oncology: human trials)Rejuvenates old haematopoietic stem cells; toxic to plateletsChang 2016, doi:10.1038/nm.4010
UBX0101 (knee injection)p53/MDM2 interactionHuman phase 2 trial (n=183)Failure: no better than placebo on pain at 12 weeks (August 2020); programme stoppedUnity Biotechnology press release, https://www.globenewswire.com/news-release/2020/08/17/2079116/0/en/unity-biotechnology-announces-12-week-data-from-ubx0101-phase-2-clinical-study-in-patients-with-painful-osteoarthritis-of-the-knee.html
JAK inhibitors (ruxolitinib)SASP (senomorphic)Preclinical; approved for other indicationsReduce the SASP, frailty and fat dysfunction in old miceXu 2015, doi:10.1073/pnas.1515386112
RapamycinSASP via mTORPreclinical (for this effect)Reduces IL-1α translation and the SASPLaberge 2015, doi:10.1038/ncb3195
Senolytic CAR-T cells (against uPAR)Surface receptor uPARPreclinicalEliminate senescent cells; liver fibrosis corrected in miceAmor 2020, doi:10.1038/s41586-020-2403-9
Senolytic vaccine (against GPNMB)Surface antigen of senescent cellsPreclinicalImproves age-related phenotypes and extends the life of progeroid miceSuda 2021, doi:10.1038/s43587-021-00151-2

Overview of clinical trials: Chaib 2022, doi:10.1038/s41591-022-01923-y; Kirkland & Tchkonia 2020, doi:10.1111/joim.13141.

6. Open questions

  1. No universal marker: no single marker identifies a senescent cell. p16, p21, β-galactosidase and SenMayo overlap poorly depending on the tissue. A validated blood biomarker to select patients and track the effect is missing.
  2. Disappointing human results so far: UBX0101 failed, and D+Q gives modest effects limited to subgroups (Farr 2024). Is this a problem of dose, tissue, patient selection or concept?
  3. Heterogeneity: senescent cells differ from one tissue to another and do not share the same vulnerabilities. A universal senolytic is unlikely.
  4. Useful roles: eliminating senescent cells can impair wound healing (Demaria 2014) or other physiological functions. What are the long-term effects?
  5. Senolytic or senomorphic? Is it better to kill the cells or silence their SASP, and for which disease?
  6. Immunotherapies (CAR-T, vaccines): promising, but cost, safety and duration of effect remain unknown in humans.

7. References